Latest news

• ViiV builds case for switching to its two-drug HIV combinations

  48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... ViiV – which is majority owned by

• ViiV bags EU okay for new two-drug HIV therapy

  Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay

• Shingrix lifts GSK in Q1, but two more vaccines are culled

  All eyes now are on Dovato (dolutegravir/lamivudine), GSK’s new two-drug combination that was recently the first ever once-a-day two-drug regimen to be approved for treating ... ViiV chairman David Redfern said Juluca and Dovato – alongside GSK’s

• CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

  The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led

• Dovato approval key for Glaxo in HIV treatment

  Dovato (dolutegravir/lamivudine) is marketed by GSK-led joint venture ViiV, and is the first ever once-a-day two-drug STR for treating treatment-naïve patients. ... seen whether or not the same will be true for 2-drug STRs such as Dovato.